Prostate-Specific Antigen P704P: A Potential Drug Target Or Biomarker for Prostate Cancer

Target Name: POTEM

NCBI ID: G641455

POTEM

Prostate-Specific Antigen P704P: A Potential Drug Target Or Biomarker for Prostate Cancer

Prostate-specific P704P (Prostate-Specific Antigen P704P) is a protein that is expressed in the prostate gland and has been identified as a potential drug target or biomarker for various urological cancers, including prostate cancer. The protein is composed of 194 amino acids and has a calculated molecular weight of 21.1 kDa. It is expressed in the prostate epithelial tissue and is also found in the surrounding connective tissue.

The P704P protein is a glycoprotein and has four distinct isoforms. Isotype P704P is the most abundant isoform and is expressed in the majority of prostate epithelial cells. Isotype P704P has a molecular weight of 19.0 kDa and consists of 116 amino acids. Isotype P704P is also known as P200 and has been shown to be involved in cell signaling pathways, including the TGF-β pathway.

Isoform P704Q is the second most abundant isoform and has a molecular weight of 19.8 kDa. It is also known as P201 and has been shown to be involved in the regulation of cell growth, as well as in the development of new blood vessels in the prostate gland.

Isoform P704R is the least abundant isoform and has a molecular weight of 16.1 kDa. It is also known as P202 and has been shown to be involved in the regulation of cell adhesion and in the development of new blood vessels in the prostate gland.

The P704P protein has been shown to be involved in various signaling pathways, including the TGF-β pathway, the androgen signaling pathway, and the Wnt signaling pathway. It has also been shown to play a role in the regulation of cell growth, cell differentiation, and cell survival.

In addition to its role in cell signaling pathways, P704P has also been shown to be involved in the development of new blood vessels in the prostate gland. This is of particular interest in the context of prostate cancer, as the development of new blood vessels is a common event in the progression of this disease.

The identification of P704P as a potential drug target or biomarker for prostate cancer has led to a number of studies aimed at characterizing its functions and potential clinical applications. These studies have shown that P704P is involved in the regulation of cell signaling pathways, including the TGF-β pathway, and is involved in the development of new blood vessels in the prostate gland.

In addition to its potential clinical applications, the characterization of P704P has also provided insights into its underlying biology. The regulation of cell signaling pathways by P704P is shown to be involved in the regulation of cell growth, cell differentiation, and cell survival. This is of particular interest in the context of cancer, as the regulation of cell signaling pathways is a common event in the progression of this disease.

Overall, the protein P704P is a promising candidate for further study as a potential drug target or biomarker for prostate cancer. Further research is needed to fully understand its functions and potential clinical applications.

Protein Name: POTE Ankyrin Domain Family Member M

The "POTEM Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about POTEM comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets